S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

bluebird bio Stock Forecast, Price & News

+0.74 (+2.65 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $28.68
50-Day Range
MA: $40.74
52-Week Range
Now: $28.68
Volume1.70 million shs
Average Volume2.41 million shs
Market Capitalization$1.93 billion
P/E RatioN/A
Dividend YieldN/A
bluebird bio, Inc., a biotechnology company, engages in researching, developing, and commercializing of transformative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin for the treatment of Ã-thalassemia and sickle cell disease; and Lenti-D for the treatment of cerebral adrenoleukodystrophy. The company's product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Bristol-Myers Squibb to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets; Forty Seven, Inc. to pursue clinical proof-of-concept for an antibody-based conditioning regimen; and Novo Nordisk A/S to develop in vivo genome editing treatments for genetic diseases, as well as clinical trial collaboration with Magenta Therapeutics. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
bluebird bio logo


bluebird bio to Present at Cowen Health Care Conference
February 26, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:BLUE
Year FoundedN/A



Sales & Book Value

Annual Sales$44.67 million
Book Value$23.22 per share


Net Income$-789,610,000.00
Net Margins-256.84%


Market Cap$1.93 billion
Next Earnings Date5/10/2021 (Estimated)


Overall MarketRank

1.76 out of 5 stars

Medical Sector

193rd out of 1,972 stocks

Biological Products, Except Diagnostic Industry

23rd out of 177 stocks

Analyst Opinion: 4.1Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
+0.74 (+2.65 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BLUE News and Ratings via Email

Sign-up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

bluebird bio (NASDAQ:BLUE) Frequently Asked Questions

Is bluebird bio a buy right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 13 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" bluebird bio stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View analyst ratings for bluebird bio
or view top-rated stocks.

What stocks does MarketBeat like better than bluebird bio?

Wall Street analysts have given bluebird bio a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but bluebird bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting bluebird bio?

bluebird bio saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 6,140,000 shares, a decline of 15.0% from the December 31st total of 7,220,000 shares. Based on an average daily volume of 1,200,000 shares, the short-interest ratio is presently 5.1 days.
View bluebird bio's Short Interest

When is bluebird bio's next earnings date?

bluebird bio is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for bluebird bio

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) issued its quarterly earnings data on Monday, February, 22nd. The biotechnology company reported ($3.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.96) by $0.05. The biotechnology company had revenue of $10.71 million for the quarter, compared to analysts' expectations of $15.01 million. bluebird bio had a negative trailing twelve-month return on equity of 45.78% and a negative net margin of 256.84%. bluebird bio's quarterly revenue was up 7.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($4.04) earnings per share.
View bluebird bio's earnings history

How has bluebird bio's stock price been impacted by Coronavirus (COVID-19)?

bluebird bio's stock was trading at $61.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BLUE shares have decreased by 53.4% and is now trading at $28.68.
View which stocks have been most impacted by COVID-19

What price target have analysts set for BLUE?

17 Wall Street analysts have issued 1 year target prices for bluebird bio's stock. Their forecasts range from $27.00 to $123.00. On average, they anticipate bluebird bio's share price to reach $68.47 in the next twelve months. This suggests a possible upside of 138.7% from the stock's current price.
View analysts' price targets for bluebird bio
or view top-rated stocks among Wall Street analysts.

Who are bluebird bio's key executives?

bluebird bio's management team includes the following people:
  • Mr. Nick Leschly, Pres, CEO & Director (Age 48, Pay $1.09M)
  • Mr. William D. Baird III, Chief Financial Officer (Age 49, Pay $808.89k)
  • Mr. Jason F. Cole, Chief Operating & Legal Officer and Sec. (Age 48, Pay $619.8k)
  • Dr. Philip D. Gregory, Chief Scientific Officer (Age 50, Pay $660.8k)
  • Dr. David M. Davidson, Chief Medical Officer (Age 57, Pay $705k)
  • Ms. Katy Burnett, Principal Accounting Officer, Sr. Director & Global Controller (Age 44)
  • Dr. Derek Adams Ph.D., Chief Technology & Manufacturing Officer
  • Ms. Ingrid Goldberg, VP of Investor Relations
  • Ms. Elizabeth Pingpank, Director of Corp. Communications
  • Ms. Kathleen A. Wilkinson, Chief People Officer (Age 49)

What is Nick Leschly's approval rating as bluebird bio's CEO?

66 employees have rated bluebird bio CEO Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among bluebird bio's employees.

Who are some of bluebird bio's key competitors?

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), (CELG), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.82%), Sands Capital Management LLC (4.77%), Victory Capital Management Inc. (2.20%), First Trust Advisors LP (1.76%), Price T Rowe Associates Inc. MD (1.56%) and Armistice Capital LLC (1.31%). Company insiders that own bluebird bio stock include Alison Cecily Finger, David Davidson, Jeffrey T Walsh, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly, Philip D Gregory and William D Baird III.
View institutional ownership trends for bluebird bio

Which institutional investors are selling bluebird bio stock?

BLUE stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Great Lakes Advisors LLC, Senvest Management LLC, Alliancebernstein L.P., Barclays PLC, Victory Capital Management Inc., Sands Capital Management LLC, and EPIQ Capital Group LLC. Company insiders that have sold bluebird bio company stock in the last year include Alison Cecily Finger, David Davidson, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly, and William D Baird III.
View insider buying and selling activity for bluebird bio
or view top insider-selling stocks.

Which institutional investors are buying bluebird bio stock?

BLUE stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, JPMorgan Chase & Co., Renaissance Technologies LLC, Morgan Stanley, UBS Asset Management Americas Inc., BlackRock Inc., Candriam Luxembourg S.C.A., and Armistice Capital LLC.
View insider buying and selling activity for bluebird bio
or or view top insider-buying stocks.

How do I buy shares of bluebird bio?

Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is bluebird bio's stock price today?

One share of BLUE stock can currently be purchased for approximately $28.68.

How much money does bluebird bio make?

bluebird bio has a market capitalization of $1.93 billion and generates $44.67 million in revenue each year. The biotechnology company earns $-789,610,000.00 in net income (profit) each year or ($14.31) on an earnings per share basis.

How many employees does bluebird bio have?

bluebird bio employs 1,171 workers across the globe.

What is bluebird bio's official website?

The official website for bluebird bio is www.bluebirdbio.com.

Where are bluebird bio's headquarters?

bluebird bio is headquartered at 60 BINNEY STREET, CAMBRIDGE MA, 02142.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected]

This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.